In partnership with

Conferences

Disease Areas

Highlights from

World Conference on Lung Cancer

19th annual meeting

Toronto, Canada 23-26 September 2018

Articles

Introduction

Letter from The Editor

Interview with the IASCL President

Presidential Symposium – Top 5 abstracts

Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer

Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer

Benefits of chest CT screening

New standard of care in extensive-stage small-cell lung cancer

No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype

New aspects of immunotherapy

Next generation immunotherapy in non-small-cell lung cancer

Combination therapies: Where are we in 2018?

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

New aspects of targeted therapy

PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib

Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC

Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative

Mesothelioma

Unmet needs in surgical management of malignant pleural mesothelioma

Angiogenic and stromal biomarkers in malignant mesothelioma

Advanced non-small cell lung cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer

Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer

Novel therapies in ROS1 and EGFR

Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement

Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer

Entrectinib treatment in patients with ROS1+ NSCLC

Advances in small-cell and neuroendocrine tumours

Small-cell lung cancer circulating tumour cell derived explants

Spread through air spaces is prognostic in lung neuroendocrine tumours

Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

@IASLC